



## DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

- POLICY:** Immunologicals – Fasenra Drug Quantity Management Policy – Per Days
- Fasenra® (benralizumab subcutaneous injection – AstraZeneca)

**REVIEW DATE:** 10/29/2025

### **INSTRUCTIONS FOR USE**

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

### **CIGNA NATIONAL FORMULARY COVERAGE:**

#### **OVERVIEW**

Fasenra, an interleukin-5 receptor alpha (IL-5R $\alpha$ )-directed cytolytic monoclonal antibody, is indicated for the following uses:<sup>1</sup>

- **Asthma** as add-on maintenance treatment of patients  $\geq$  6 years of age with severe disease and an eosinophilic phenotype. Limitations of Use: Fasenra is not indicated for the treatment of other eosinophilic conditions or for the relief of acute bronchospasm/status asthmaticus.
- **Eosinophilic granulomatosis with polyangiitis** (EGPA) in adults.

#### **Dosing**

##### *Asthma Dosing*

- Adults and adolescents ≥ 12 years of age: 30 mg administered as a subcutaneous (SC) injection once every 4 weeks (Q4W) for the first 3 doses, then once every 8 weeks (Q8W) thereafter.<sup>1</sup>
- Patients 6 to 11 years of age:
  - Weight < 35 kg: 10 mg SC Q4W for the first 3 doses, then Q8W thereafter.
  - Weight ≥ 35 kg: 30 mg SC Q4W for the first 3 doses, then Q8W thereafter.

### *Eosinophilic Granulomatosis with Polyangiitis Dosing*

The recommended dose of Fasenera in patients with EGPA is 30 mg Q4W.<sup>1</sup>

### **Availability**

Fasenera is available as 10 mg/0.5 mL and 30 mg/mL single-dose, prefilled syringes and a 30 mg/mL single-dose pen.<sup>1</sup> Each carton contains one pen or syringe.

### **POLICY STATEMENT**

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Fasenera. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. Approvals are provided for 1 year in duration, unless otherwise noted below. "One-time" approvals are provided for the duration noted below.

### **Drug Quantity Limits**

<b>Product</b>	<b>Strength and Form</b>	<b>Retail and Home Delivery Maximum Quantity per 56 days</b>
Fasenera® (benralizumab subcutaneous injection)	10 mg/0.5 mL prefilled syringes	1 syringe (0.5 mL)
	30 mg/mL prefilled syringes	1 mL (1 syringe)
	30 mg/ mL prefilled pens	1 mL (1 pen)

**EXCEPTIONS TO THE QUANTITY LIMITS LISTED ABOVE ARE COVERED AS MEDICALLY NECESSARY WHEN THE FOLLOWING CRITERIA ARE MET. ANY OTHER EXCEPTION IS CONSIDERED NOT MEDICALLY NECESSARY.**

### **CRITERIA**

#### Fasenera 10 mg/0.5 mL prefilled syringes

1. If the patient is initiating therapy at induction dosing for asthma, as verified by the absence of claims for Fasenera in the past 130 days, approve a one-time override for 84 days for 3 syringes (1.5 mL) at retail and home delivery.

#### Fasenera 30 mg/mL pens and prefilled syringes

1. If the patient is initiating therapy at induction dosing for asthma, as verified by the absence of claims for Fasenera in the past 130 days, approve a one-time override for 84 days for 3 mL (3 pens or 3 prefilled syringes) at retail and at home delivery.
2. If the patient has eosinophilic granulomatosis with polyangiitis, approve 1 mL (1 pen or 1 syringe) per 28 days at retail and 3 mL (3 pens or 3 syringes) per 84 days at home delivery.

## REFERENCES

1. Fasenra® subcutaneous injection [prescribing information]. Wilmington, DE: AstraZeneca; September 2024.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	08/04/2023
Early Annual Revision	<b>Fasenra 10 mg/0.5 mL prefilled syringes:</b> New quantity limit of 0.5 mL (1 syringe) per 56 days at retail and home delivery was added to the policy. Clinical override criteria apply.	07/17/2024
Selected Revision	<b>Fasenra 30 mg/mL pens and prefilled syringes:</b> A new override for 1 mL (1 pen or syringe) per 28 days at retail and 3 mL (3 pens or syringes) per 84 days at home delivery if the patient has eosinophilic granulomatosis with polyangiitis was added to the policy.	09/25/2024
Annual Revision	Policy Statement was updated to clarify that "one-time" approvals are provided for 30 days in duration.	07/03/2025
Early Annual Revision	Policy Statement was updated to clarify that approvals are provided for 1 year in duration unless otherwise noted in criteria and "one-time" overrides are provided for the duration noted in criteria. Previously, the Policy Statement indicated that approvals were provided for the duration noted in criteria and "one-time" approvals were provided for 30 days in duration.  <b>Fasenra 10 mg/0.5 mL prefilled syringes and 30 mg/mL pens and prefilled syringes:</b> The one-time overrides for a patient who is initiating therapy at induction dosing for asthma were updated to approve for 84 days.	10/29/2025

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.